Skip to main content

Table 2 Changes of lipid metabolism before and after treatment in two groups

From: Effect of sacubitril/valsartan on lipid metabolism in patients with chronic kidney disease combined with chronic heart failure: a retrospective study

Indexes

Times

Sacubitril/valsartan (n = 106)

Valsartan (n = 106)

P

TC (mmol/L) a

Before

4.46 ± 1.28

4.51 ± 1.35

0.780

16 weeks

3.68 ± 1.12***

3.96 ± 1.36***

0.096

TG (mmol/L) b,c

Before

1.87(1.65,2.32)

1.84(1.35,2.36)

0.254

16 weeks

1.13(0.84,1.55)***

1.47(1.15,2.01)***

< 0.001

HDL-C (mmol/L) a

Before

1.10 ± 0.31

1.13 ± 0.33

0.528

16 weeks

1.24 ± 0.33***

1.13 ± 0.34

0.023

LDL-C (mmol/L) a

Before

2.60 ± 1.04

2.68 ± 1.15

0.589

16 weeks

2.05 ± 0.90***

2.17 ± 1.03***

0.338

ApoA (mmol/L) a

Before

1.12 ± 0.25

1.13 ± 0.24

0.809

16 weeks

1.23 ± 0.27***

1.15 ± 0.26

0.030

ApoB (mmol/L) a

Before

0.87 ± 0.28

0.89 ± 0.30

0.648

16 weeks

0.75 ± 0.26***

0.82 ± 0.28**

0.066

ΔTG (mmol/L) b,c

Decrease from baseline

0.84(0.40,1.14)

0.27(−0.11,0.69)

< 0.001

  1. TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ApoA apolipoprotein A, ApoB apolipoprotein B, ΔTG pre-treatment minus post-treatment
  2. a T test
  3. b Mann-Whitney U test
  4. c Wilcoxon rank sum test
  5. Data with normal distribution is represented as mean ± standard deviation, median (quartile) is used to represent data with nonnormal distribution
  6. **P < 0.01, ***P < 0.001 compared with before treatment